S-1联合内分泌辅助治疗ER阳性HER2阴性原发性乳腺癌的III期随机对照试验
这项多中心开放标签III期试验纳入1930例ER阳性HER2阴性I-IIIB期乳腺癌患者,随机接受5年内分泌治疗±1年S-1。S-1组3级及以上不良事件包括中性粒细胞减少(8% vs 1%)和腹泻(2% vs 0)。
要点
- S-1联合内分泌辅助治疗显著改善ER阳性HER2阴性中高危乳腺癌的侵袭性疾病无生存。
- S-1组3级及以上中性粒细胞减少发生率8%,需关注血液学毒性。
- 该联合方案可能成为中高危ER阳性HER2阴性乳腺癌的潜在治疗选择。
核心结论
- S-1联合内分泌辅助治疗可显著改善ER阳性HER2阴性原发性乳腺癌患者的侵袭性疾病无生存。
研究设计与样本
- 多中心、开放标签、随机对照III期试验,在139个中心(137家医院和2家诊所)开展。
- 纳入1930例20-75岁组织学诊断的I-IIIB期浸润性乳腺癌女性患者(中高复发风险),全分析集957例接受内分泌+S-1,973例接受单纯内分泌治疗。
- 随机化按1:1最小化法,分层因素包括年龄、腋窝淋巴结转移、术前或术后化疗、术前内分泌治疗、ER阳性细胞比例和研究站点。
- 主要终点为侵袭性疾病无生存,本次报告为数据截止2019年1月31日的中期分析。
主要发现
- 因中期分析时主要终点已达到,试验提前终止。
- 最常见3级及以上不良事件:中性粒细胞减少(S-1组72/954例[8%] vs 单纯内分泌组7/970例[1%])、腹泻(18例[2%] vs 无)、白细胞减少(15例[2%] vs 2例[<1%])、乏力(6例[<1%] vs 无)。
- 严重不良事件:单纯内分泌组9/970例(1%),内分泌+S-1组25/954例(3%)。
- 内分泌+S-1组有1例(<1%)可能治疗相关死亡,疑似肺动脉血栓形成。
关键数值与推荐
- S-1口服80-120 mg/天,每日两次,连用14天休7天,共1年。
- 标准辅助内分泌治疗共5年(选择性雌激素受体调节剂±卵巢抑制和芳香化酶抑制剂)。
临床怎么用
- 对于中高复发风险的ER阳性HER2阴性原发性乳腺癌患者,可考虑在标准辅助内分泌治疗基础上加用1年S-1。
- 治疗期间需密切监测中性粒细胞计数和腹泻等不良反应。
局限性
- 本次报告为中期分析结果,随访时间尚不成熟。
- 试验因主要终点提前达到而提前终止,可能高估疗效。
- 开放标签设计可能影响不良事件报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral fluoropyrimidines, such as S-1, have been shown to have a role in controlling disease progression in metastatic breast cancer. We examined adjuvant treatment with S-1 in patients with oestrogen receptor (ER)-positive and HER2-negative primary breast cancer. METHODS: We did a multicentre, open-label, randomised, controlled, phase 3 trial in 139 sites (137 hospitals and two clinics). Eligible patients were women aged 20-75 years with histologically diagnosed stage I to IIIB invasive breast cancer (intermediate to high risk of recurrence). Patients were temporarily registered at participating institutions and biopsy or surgical samples were collected and sent for central pathological assessment. Patients received 5 years of standard adjuvant endocrine therapy (selective oestrogen receptor modulators with or without ovarian suppression and aromatase inhibitors) with or without 1 year of S-1. Oral S-1 80-120 mg/day was administered twice a day for 14 days with 7 days off. Randomisation (1:1) using the minimisation method was done with six stratification factors (age, axillary lymph node metastasis at surgery or sentinel lymph node biopsy, preoperative or postoperative (neoadjuvant or adjuvant) chemotherapy, preoperative endocrine therapy, proportion of ER-positive cells, and study site). The primary endpoint was invasive disease-free survival, in the full analysis set (all randomly assigned patients, excluding those with significant protocol deviations). The safety analysis set consisted of all patients who received at least one dose of study treatment. Here, we report the results from the interim analysis at the data cutoff date Jan 31, 2019. This trial is registered with Japan Registry of Clinical Trials, jRCTs051180057, and the University hospital Medical Information Network, UMIN000003969. FINDINGS: Between Feb 1, 2012, and Feb 1, 2016, 1930 patients were enrolled in the full analysis set, 957 (50%) received endocrine therapy plus S-1 and 973 (50%) received endocrine therapy alone. Median follow-up was 52·2 months (IQR 42·1-58·9). 155 (16%) patients in the endocrine therapy alone group and in 101 (11%) patients in the endocrine therapy plus S-1 group had invasive disease-free survival events (hazard ratio 0·63, 95% CI 0·49-0·81, p=0·0003). As the primary endpoint was met at interim analysis, the trial was terminated early. The most common grade 3 or worse adverse events were decreased neutrophil count (72 [8%] of 954 patients in the endocrine therapy plus S-1 group vs seven [1%] of 970 patients in the endocrine therapy alone group), diarrhoea (18 [2%] vs none), decreased white blood cells (15 [2%] vs two [<1%]), and fatigue (six [<1%] vs none). Serious adverse events were reported in nine (1%) of 970 patients in the endocrine therapy alone group and 25 (3%) of 954 patients in the endocrine therapy plus S-1 group. There was one (<1%) possible treatment-related death in the endocrine therapy plus S-1 group due to suspected pulmonary artery thrombosis. INTERPRETATION: These data suggest that this combination of S-1 with endocrine therapy could be a potential treatment option for this intermediate and high-risk group of patients with ER-positive, HER2-negative primary breast cancer. FUNDING: Public Health Research Foundation (Japan), Taiho Pharmaceutical.
引用
- Toi M, Imoto S, Ishida T, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021. PMID: 33387497. doi:10.1016/S1470-2045(20)30534-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。